AOD-9604 vs Hexarelin
A comprehensive, data-driven comparison of AOD-9604 (Advanced Obesity Drug) and Hexarelin (Examorelin). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | AOD-9604 Advanced Obesity Drug, Tyr-hGH Fragment 176-191 | Hexarelin Examorelin |
|---|---|---|
| FDA Status | Phase 2 (failed; reclassification pending) | Not submitted |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Fat loss and metabolism enhancement | Growth hormone optimization and cardiac protection |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $30 - $60/mo | $40 - $80/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 300mcg daily | 100-200mcg 2x daily (pulsed use recommended) |
| Frequency | Daily | Daily |
| Mechanism | Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without affecting blood sugar or IGF-1 | Potent growth hormone secretagogue with cardioprotective properties beyond GH stimulation |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Low | Emerging |
| Clinical Trial Phase | Phase 2 | N/A |
Key Differences
- 1AOD-9604 is generally more affordable ($30 - $60/mo) compared to Hexarelin ($40 - $80/mo).
- 2AOD-9604 has low-quality evidence, while Hexarelin has emerging-quality evidence.
- 3They belong to different categories: AOD-9604 (Weight Loss) vs Hexarelin (Growth Hormone).
Which Is Better For...
AOD-9604
More budget-friendly option with lower monthly costs
AOD-9604
Fewer commonly reported side effects
AOD-9604
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| AOD-9604 | $30 - $60/mo | Phase 2 (failed; reclassification pending) | Various research labs |
| Hexarelin | $40 - $80/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
AOD-9604 works via Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis. Hexarelin works via Potent growth hormone secretagogue with cardioprotective properties beyond GH stimulation. They differ in FDA approval status, efficacy data, and cost.
AOD-9604 typically costs $30 - $60/mo, while Hexarelin costs $40 - $80/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
AOD-9604 is not FDA-approved (Phase 2 (failed; reclassification pending)). Hexarelin is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of AOD-9604 include Injection site reactions, Headache, Chest tightness (rare). Common side effects of Hexarelin include Increased appetite, Cortisol elevation, Prolactin elevation. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
AOD-9604 is a modified peptide fragment of the C-terminus of human growth hormone (amino acids 176-191). It was designed to retain the fat-burning properties of HGH while avoiding effects on blood sug...
View Full AOD-9604 GuideHexarelin is a synthetic hexapeptide GH secretagogue that is significantly more potent than GHRP-6. Beyond stimulating growth hormone release, research has revealed unique cardioprotective effects ind...
View Full Hexarelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between AOD-9604 and Hexarelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.